Compare ViroGates A/S with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
DKK 113 Million ()
NA (Loss Making)
NA
0.00%
-0.15
-436.97%
39.95
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Sep 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
36.31%
0%
36.31%
6 Months
-2.4%
0%
-2.4%
1 Year
68.28%
0%
68.28%
2 Years
-27.75%
0%
-27.75%
3 Years
-80.85%
0%
-80.85%
4 Years
-91.58%
0%
-91.58%
5 Years
-77.07%
0%
-77.07%
ViroGates A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.44%
EBIT Growth (5y)
7.43%
EBIT to Interest (avg)
-14.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
0.60
Tax Ratio
5.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
20.95
EV to EBIT
-7.43
EV to EBITDA
-7.43
EV to Capital Employed
-44.96
EV to Sales
20.71
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-266.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1.70
0.70
142.86%
Operating Profit (PBDIT) excl Other Income
-2.00
-3.10
35.48%
Interest
0.10
0.30
-66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.90
-3.20
40.62%
Operating Profit Margin (Excl OI)
-1,215.20%
-4,676.20%
346.10%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 142.86% vs -41.67% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 40.62% vs -14.29% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4.90
5.60
-12.50%
Operating Profit (PBDIT) excl Other Income
-16.80
-12.50
-34.40%
Interest
0.70
0.60
16.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-14.30
-12.10
-18.18%
Operating Profit Margin (Excl OI)
-3,431.70%
-2,251.00%
-118.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -12.50% vs -45.10% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -18.18% vs -26.04% in Dec 2023
About ViroGates A/S 
ViroGates A/S
Pharmaceuticals & Biotechnology
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Company Coordinates 
Company Details
Banevaenget 13 , BIRKEROED None : 3460
Registrar Details






